Efavaleukin alfa clinical trials
Also written AMG 592.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses efavaleukin alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses efavaleukin alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisTerminatedPhase 2AmgenNCT04987307Written as Efavaleukin alfa
- Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisTerminatedPhase 2AmgenNCT05672199Written as Efavaleukin alfa
- Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus ErythematosusTerminatedPhase 2AmgenNCT04680637Written as Efavaleukin Alfa
- Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian ParticipantsCompletedPhase 1AmgenNCT04987333Written as Efavaleukin alfa
- Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host DiseaseTerminatedPhase 1/2AmgenNCT03422627Written as Efavaleukin Alfa
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus ErythematosusCompletedPhase 1AmgenNCT03451422Written as Efavaleukin Alfa
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese ParticipantsCompletedPhase 1AmgenNCT05885451Written as AMG 592
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy ParticipantsCompletedPhase 1AmgenNCT05873907Written as AMG 592
- Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid ArthritisTerminatedPhase 1/2AmgenNCT03410056Written as Efavaleukin alfa
Codes
What other systems call efavaleukin alfa · ClinicalTrials.gg INT018606
- UNII (FDA) YNH9K62UXUEFAVALEUKIN ALFAOne source FDA
- NCI Thesaurus C169929Efavaleukin AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YNH9K62UXU | EFAVALEUKIN ALFA | One source FDA |
| NCI Thesaurus | C169929 | Efavaleukin Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.